david j kerr
david j kerr
00441865 220356
Adresse e-mail validée de ndcls.ox.ac.uk - Page d'accueil
Citée par
Citée par
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
JP Neoptolemos, DD Stocken, H Friess, C Bassi, JA Dunn, H Hickey, ...
New England Journal of Medicine 350 (12), 1200-1210, 2004
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making
HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ...
Annals of oncology 23 (10), 2479-2516, 2012
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial
JP Neoptolemos, JA Dunn, DD Stocken, J Almond, K Link, H Beger, ...
The Lancet 358 (9293), 1576-1585, 2001
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
N Bhala, J Emberson, A Merhi, S Abramson, N Arber, JA Baron, ...
Lancet (London, England) 382 (9894), 769-779, 2013
A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24. 21
I Tomlinson, E Webb, L Carvajal-Carmona, P Broderick, Z Kemp, S Spain, ...
Nature genetics 39 (8), 984-988, 2007
Genetic prognostic and predictive markers in colorectal cancer
A Walther, E Johnstone, C Swanton, R Midgley, I Tomlinson, D Kerr
Nature Reviews Cancer 9 (7), 489-499, 2009
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas
C Palles, JB Cazier, KM Howarth, E Domingo, AM Jones, P Broderick, ...
Nature genetics 45 (2), 136-144, 2013
Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.
DR Ferry, A Smith, J Malkhandi, DW Fyfe, PG deTakats, D Anderson, ...
Clinical cancer research 2 (4), 659-668, 1996
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
DJ Sargent, HS Wieand, DG Haller, R Gray, JK Benedetti, M Buyse, ...
Journal of Clinical Oncology 23 (34), 8664-8670, 2005
Delivering affordable cancer care in high-income countries
R Sullivan, J Peppercorn, K Sikora, J Zalcberg, NJ Meropol, E Amir, ...
The lancet oncology 12 (10), 933-980, 2011
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial
JP Neoptolemos, DD Stocken, JA Dunn, J Almond, HG Beger, P Pederzoli, ...
Annals of surgery 234 (6), 758, 2001
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23. 3
IPM Tomlinson, E Webb, L Carvajal-Carmona, P Broderick, K Howarth, ...
Nature genetics 40 (5), 623-630, 2008
Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer
G Hutchins, K Southward, K Handley, L Magill, C Beaumont, ...
J Clin Oncol 29 (10), 1261-1270, 2011
A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk
P Broderick, L Carvajal-Carmona, AM Pittman, E Webb, K Howarth, ...
Nature genetics 39 (11), 1315-1317, 2007
Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer
C Study
Nature genetics 40 (12), 1426, 2008
Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey
P Stone, A Richardson, E Ream, AG Smith, DJ Kerr, N Kearney, ...
Annals of oncology 11 (8), 971-975, 2000
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer
R Salazar, P Roepman, G Capella, V Moreno, I Simon, C Dreezen, ...
Journal of clinical oncology 29 (1), 17-24, 2011
Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus
JA Jankowski, NA Wright, SJ Meltzer, G Triadafilopoulos, K Geboes, ...
The American journal of pathology 154 (4), 965-973, 1999
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin
LW Seymour, DR Ferry, D Anderson, S Hesslewood, PJ Julyan, R Poyner, ...
Journal of clinical oncology 20 (6), 1668-1676, 2002
The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumor Site, Type of …
A Russo, V Bazan, B Iacopetta, D Kerr, T Soussi, N Gebbia
Journal of clinical oncology 23 (30), 7518-7528, 2005
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20